CLVT Stock Recent News

New five-year agreement delivers critical academic and life sciences insights into more than 400 institutions, broadening access and driving national research excellence LONDON , June 2, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the renewal of its multi-year partnership with CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior), significantly expanding access to trusted Academia & Government and Life Sciences & Healthcare data across over 400 Brazilian institutions. As compared to the previous contract, the agreement increases institutional coverage by 57%, extending the reach of high-quality research tools to universities and research centers across Brazil — from major metropolitan areas to the country's most remote regions.

New AI-based solution empowers trademark professionals to evaluate trademark risk and generate evidence-backed arguments with speed, ease, and confidence LONDON , May 19, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of RiskMark, an AI-powered solution combining global CompuMark trademark data and Darts-ip litigation data to evaluate trademark risk. Leveraging 172.5 million trademark records spanning 188 jurisdictions and over 5 million global court and administrative records, RiskMark combines generative and predictive AI to transform the process of assessing similarity risk based on relevant evidence.

Procter & Gamble, Nestlé, Apple, L'Oréal, Novartis, LG Electronics and Unilever among the largest portfolio owners in most registers LONDON , May 15, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the Trademark filing trends 2025 report, analyzing ten key trademark registers worldwide: the United States (U.S.), Canada, the United Kingdom (U.K.), the European Union (EU), France, Germany, India, Mainland China, Japan, and Australia. The report reveals the top 20 largest local and foreign-based trademark portfolios in each region and the law firms managing the largest trademark portfolios.

R&D teams can streamline safety evaluations, reduce risks and enable faster decision-making in drug development using new visual and data-driven insights LONDON , May 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the incorporation of Pathway Maps in OFF-X, a cutting-edge translational safety intelligence solution. With over 30% of drug development failures attributed to safety issues1, preclinical and translational research teams face increasing pressure to identify potential liabilities earlier in the target selection process.

I rate Clarivate a buy, as 1Q25 marks a potential turning point with positive organic growth driven by stronger renewals and a healthier recurring revenue mix. CLVT's recurring revenue now makes up 83% of total sales, with organic recurring revenue growing by 0.6% y/y, indicating improved fundamentals. The IP segment shows promise, with 1.3% y/y organic growth, driven by stronger patent renewals and new AI tools like Derwent's AI-powered search feature.

DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Life Science Analytics Market , valued at US$35.69 billion in 2024, is forecasted to grow at a robust CAGR of 11.4%, reaching US$40.03 billion in 2025 and an impressive US$68.81 billion by 2030. The standardization of diverse datasets from sources such as clinical trials, electronic health records (EHRs), genomics, and real-world evidence is essential for the efficient exchange of information across various platforms and geographical regions. This standardization enhances multi-site clinical trials and cross-border research collaborations. Additionally, emerging technologies like artificial intelligence (AI), quantum computing, and cognitive computing play a vital role in transforming large volumes of raw data into actionable insights. These technologies help simplify reports and create interactive dashboards. Furthermore, the increasing adoption of analytics in pre-clinical trials, drug discovery, and clinical trials, particul

Clarivate Plc (NYSE:CLVT ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Mark Donohue - Vice President, Investor Relations Matti Shem Tov - Chief Executive Officer Jonathan Collins - Chief Financial Officer Conference Call Participants Greg Parrish - Morgan Stanley David Paige - RBC Capital Markets Shlomo Rosenbaum - Stifel George Tong - Goldman Sachs Surinder Thind - Jefferies Operator Thank you for joining ladies and gentlemen. My name is Karen, I'll be your conference operator.

The headline numbers for Clarivate (CLVT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Clarivate PLC (CLVT) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.14 per share a year ago.

— Accelerated recurring organic revenue growth — — Reaffirmed 2025 Outlook — — Repurchased $50 million ordinary shares — LONDON , April 29, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2025. Total revenues for the first quarter of 2025 was $593.7 million, compared to total revenues of $621.2 million for the first quarter of 2024.